A Study to Test if TEV-53275 is Effective in Relieving Asthma

Study Title
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma
Teva Identifier
TV53275-AS-20033
ClinicalTrials.gov Identifier
NCT04847674
Study Status
Terminated
Trial Condition(s)
Asthma
Interventions
Drug: TEV-53275 Dose A | Drug: TEV-53275 Dose B | Drug: Placebo
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
respiratory-icon

Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years and Older
Trial Duration
May 4, 2021 - April 28, 2022
Phase
Phase 2

Study Type

Interventional